((自动化翻译由路透提供，请见免责声明 ))
11月1日 - ** 生物制药公司 Halozyme Therapeutics 的 股价盘前上涨 14.7% 至 58.01 美元
** 受特许权使用费收入和产品销售额增长的推动，该公司将24财年的收入预期从之前的9.35亿美元至10.2亿美元上调至9.7亿美元至10.2亿美元。
** 光环公司预计 24 财年每股副利润介于 4.00 美元至 4.20 美元之间，而之前的预测为每股 3.65 美元至 4.05 美元。
** 预计特许权使用费收入为 5.5 亿至 5.65 亿美元，比上年增长 23% 至 26%。
** 根据 LSEG 的数据，该公司第三季度每股收益为 1.27 美元，高于分析师预计的每股 98 美分。
** 覆盖该股的分析师的平均评级为 "买入"；PT 中位数为 63 美元 - LSEG 数据
** 截至上次收盘，该股今年累计上涨 36.8%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.